ResultsIQ

ResultsIQ › Latest results › Ennature Bio Pharma Limited

Ennature Bio Pharma Limited (ENNATURE) quarterly results

NSE: ENNATURE · BSE: 545012

Ennature Bio Pharma Limited Q2 FY27 results

As filed: Revenue ₹78.5 cr, EBITDA ₹10.3 cr, PAT ₹4.9 cr, EBITDA margin 13.2%.

Not scored. No result for the same quarter last year.

Figures from the company's filings with NSE and BSE. Not investment advice.

About Ennature Bio Pharma Limited

Ennature Bio Pharma makes plant-based active pharmaceutical ingredients, guar-gum biopolymers and nutraceutical ingredients, and was demerged from India Glycols.

What Ennature Bio Pharma Limited does

Develops and manufactures value-added, plant-based ingredients for the pharmaceutical, nutraceutical and food & beverage industries. Makes plant-derived APIs, ultra-pure nicotine and guar-gum biopolymers. Operates three segments: active pharmaceutical ingredients (API), biopolymers and nutraceuticals. Raw materials are sourced primarily from India through direct farmer partnerships.

How it makes money

  • APIs are 67 per cent of sales; the portfolio includes thiocolchicoside, colchicine, nicotine and vinpocetine, with exports at 54 per cent of segment revenue in FY26.
  • Biopolymers, focused on guar gum and specialty gums, are 16 per cent of sales with 69 per cent export contribution in FY26.
  • Nutraceuticals are 17 per cent of sales, with exports at 83 per cent of segment revenue in FY26.
  • Reported net revenue of ₹246 crore, EBITDA of ₹29 crore and a gross margin of 40.1 per cent for FY26.

Customers and markets

  • API business serves over 150 customers across 26 countries, with exports at 54 per cent of segment revenue in FY26.
  • Biopolymer segment has customers across 23 countries, with exports at 69 per cent of FY26 revenues.
  • Nutraceutical segment serves more than 90 customers across over 19 countries, with exports at 83 per cent of revenues in FY26.
  • Exports to 30+ countries, with markets listed in Asia, Europe, the Americas, and the Middle East & Africa.

Plants and capacity

  • Dehradun: SCFE plant, solvent refining, bio-fermentation, pilot and scale-up plants, and a formulation facility., capacity 1,600 metric tonnes (2026)
  • Kashipur: Manufacturing facility, capacity 24,000 metric tonnes (2026)

Segments

  • Active pharmaceutical ingredients (API): 67 per cent of sales, FY26
  • Biopolymers: 16 per cent of sales, FY26
  • Nutraceuticals: 17 per cent of sales, FY26

Key facts

  • Founded: Established in 2009 as the natural-ingredients division of India Glycols (2009)
  • Listing: Listed on NSE and BSE on November 4, 2026, after demerger from India Glycols Ltd (2026)
  • Patents: Nine patents filed, five granted, four under review (2026)
  • Clinical trials: 20 clinical trials (2026)
  • Parent: 100% subsidiary of India Glycols Limited (2026)

What the company says sets it apart

  • The company says it has one of India's largest supercritical-fluid extraction facilities, at its Dehradun site.
  • The company says it holds WHO-GMP, ISO 9001:2015, ISO 22000:2018, EU-GMP with CEP, HACCP, Halal and Kosher certifications, backed by a 21 CFR Part 11-compliant quality system.
  • The company says it produces its own sugarcane-based green CO₂ and solvents, treats 100% of effluent through a zero-discharge system, and that plant residue supplies over 70% of its fuel.
  • The company says it is a global leader in Thiocolchicoside API by export volume.
  • The company says its SCEMOD™ platform showed a 1,000× improvement in active solubility with Xanthogreen® lutein esters (20% vs. 0.02%).

The company's own claims, as stated in its filings and website.

AI-written from 8 public sources; every line links its source on the page.